Massachusetts General Hospital Cancer Center

https://www.massgeneral.org/cancer-center

 

Massachusetts General Hospital Cancer Center
K

Tumor Infiltrating Lymphocytes: What Is the Data That Supports the Predictive Power of Seeing CD8 Positive T-Cells in the Tumor?

By Massachusetts General Hospital Cancer Center FEATURING Keith Flaherty
By Massachusetts General Hospital Cancer Center FEATURING Keith Flaherty
18 views
February 5, 2021
Comments 0
Login to view comments. Click here to Login
Videos
09:39

New

Overcoming Clinical Barriers: Integrating Liposomal Irinotecan Into …

Massachusetts General Hospital Cancer Center

P. Pathak

08:10

New

ASH 2024 Insights: Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen…

2024 ASH Annual Meeting Insights Hub

J. Soumerai

59 views
09:51

New

ASH 2024 Insights: Sonrotoclax + Zanubrutinib in 1L CLL - Results Fr…

2024 ASH Annual Meeting Insights Hub

J. Soumerai

30 views
05:36

New

ASH 2024 Insights: Ziftomenib + Ven/Aza in R/R NPM1mut or KMT2A-r AM…

2024 ASH Annual Meeting Insights Hub

A. Fathi

24 views
18:48

New

Proton-Based Radiation Therapy for Chordomas

Massachusetts General Hospital Cancer Center

F. Giap

14:31

Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia:…

Massachusetts General Hospital Cancer Center

H. Al-Samkari

54 views
26:55

Understanding ESR1 Mutations in HR+/HER2- mBC: Testing Methods, Pati…

Massachusetts General Hospital Cancer Center

S. Wander

319 views
11:21

Uveal Melanoma for Community Oncologists

Massachusetts General Hospital Cancer Center

K. Montazeri

114 views
14:06

2023 SMR Congress Insights: "Time-to-Event Machine Learning Predicti…

Insights from 2023 Society for Melanoma Research Annual Meeting

Y. Semenov

60 views
18:31

SOHO 2023: CAR/BsAb Toxicity in MM - Prevention, Treatment, and Surv…

SOHO 2023 Eleventh Annual Meeting

N. S. Raje

161 views
10:42

Updated Data for Ziftomenib in Adults With NPM1-Mutated R/R AML

Insights from 2023 EHA® Annual Meeting

A. Fathi

242 views
06:25

ASCO® 2023 Insights: "Phase 1/2 TRIDENT-1 Trial - Intracranial and S…

Insights from 2023 ASCO® Annual Meeting

J. Lin

86 views
16:49

ESR1 Mutations in HR+/HER2- mBC and Their Role in Treatment Outcomes

Massachusetts General Hospital Cancer Center

S. Wander

251 views
17:54

Genetic Heterogeneity in Brain Metastases and Implications for Clini…

Massachusetts General Hospital Cancer Center

P. Brastianos

15 views
09:52

Maintenance Therapy in AML: Protecting Remission, Extending Survival…

Massachusetts General Hospital Cancer Center

A. Brunner

219 views
08:20

ESMO 2021 Updates on 1L DKN-01 + Tislelizumab & Chemotherapy in Adva…

Massachusetts General Hospital Cancer Center

S. Klempner

110 views
12:08

Selpercatinib Efficacy & Safety in Patients With RET-Altered Thyroid…

Massachusetts General Hospital Cancer Center

L. Wirth

43 views
10:05
i3 Health

Emerging Treatment Strategies for Advanced Cholangiocarcinoma: Molec…

Feat. L. Goyal
50:37

Next Steps in FGFRi in Cholangiocarcinoma: FGFR Pathway & Current La…

Massachusetts General Hospital Cancer Center

L. Goyal

238 views
04:27

ASCO 2021 Highlights From GEOMETRY mono-1 Study on Advanced NSCLC: C…

Massachusetts General Hospital Cancer Center

R. Heist

40 views
16:46

2021 Updates on mTNBC: Do Olaparib/Talazoparib Improve PFS Compared …

Virtual West Oncology Conference

N. Vidula

72 views
18:15

Targeted Therapy for EGFR+ NSCLC: What Are the Current Options Upon …

GRACE

Z. Piotrowska

104 views
10:33

Targeted Therapy for EGFR+ NSCLC: How Do We Think About Acquired Res…

GRACE

Z. Piotrowska

114 views
31:44

Tumor Infiltrating Lymphocytes: What Is the Data That Supports the P…

Massachusetts General Hospital Cancer Center

K. Flaherty

18 views
13:52

Targeting Exon 20 Insertions in NSCLC: Anti-Tumor Activity With T-Dx…

2020 ASCO Virtual Direct™ Highlights

I. Dagogo-Jack

327 views
05:44

2020 ESMO Update on Targeted Therapy in NSCLC: Can We Safely Combine…

2020 Virtual ESMO Review

I. Dagogo-Jack

29 views
07:33

2020 ESMO Update on Targeted Therapy in NSCLC: Does ADAURA Trial Sug…

2020 Virtual ESMO Review

I. Dagogo-Jack

177 views
07:14

2020 ESMO Update on ADCs in mTNBC: Is Sacituzumab Govitecan More Ben…

ecancer

A. Bardia

273 views
13:34
2020 Virtual ESMO Review

2020 ESMO Update on Targeted Therapy in NSCLC: Can We Safely Combine…

Feat. I. Dagogo-Jack
26:39

Risk Factors in Lung Cancer: Which Risk Factor Is Predominant? How I…

Virtual Diversity in Cancer Care

I. Dagogo-Jack

157 views